Telix Pharmaceuticals and Radboud University Medical Centre Conclude Clinical Collaboration Agreement
MELBOURNE, Australia and NIJMEGAN, The Netherlands, March 15, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) ("Telix", the "Company"), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or "molecularly-targeted radiation" (MTR), has today announced a clinical collaboration with Radboud University Medical Center ("Radboudumc").
Telix is developing 89Zr-girentuximab (TLX-250) for the purpose of imaging clear cell renal cell cancer (ccRCC) with Positron Emission Tomography (PET). Radboudumc and Telix will collaborate on several clinical projects in relation to TLX-250, including leading the pre-Phase III bridging/dosimetry study for TLX-250, participating as a key adviser for the Phase III study, as well as the IMPACT-RCC study (NCT02228954) to better understand how molecular imaging can be used to measure therapeutic treatment response in metastatic kidney cancer.
Telix Co-Founder and CMO Dr. Andreas Kluge stated, "Radboudumc has been a clinical leader in the use of 89Zr-Girentuximab (TLX-250) in the clinic and their patient experience underpins much of the confidence we have in the imaging agent, particularly the change in isotope to a radiometal for superior image quality, sensitivity and patient convenience. We have worked closely with Radboudumc as part of activating our clinical activity for TLX-250 in Europe."
Professor Peter Mulders, Chairman of the Department of Urology at Radboudumc noted, "We are pleased to be working with Telix to progress this very important technology from a clinical perspective. This international collaboration lays the foundation for the completion of product development of 89Zr-Girentuximab and we are delighted to be part of bringing this technology to renal cancer patients in the Netherlands and beyond."
As part of the collaboration, Telix will fund a clinical fellowship position at the Department of Radiology and Nuclear Medicine of the Radboudumc to oversee the various activities around the collaboration. The Radboudumc Technology Center imaging facility will also be a key partner, with its cutting-edge technology and expertise for pre-clinical and clinical imaging.
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited (Telix) is a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or "molecularly-targeted radiation" (MTR). The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (JP) and Indianapolis (US). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Telix is listed on the Australian Securities Exchange (ASX:TLX).
For more information visit www.telixpharma.com.
About Radboud University Medical Center (Radboudumc)
The Radboud University Medical Center, is the academic hospital affiliated with the Radboud University Nijmegen, in the city of Nijmegen in the eastern-central part of The Netherlands. It is one of the largest and leading hospitals of The Netherlands, providing supra-regional tertiary care for residents of a large part The Netherlands. The medical center has 1,000 beds, employs approximately 10,000 employees, and offers educational services to about 3,000 students.
For more information visit www.radboudumc.nl.
This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "US Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available.
None of the products described in this release have obtained a marketing authorization from the US Food and Drug Administration.
Corporate Contact Dr Christian Behrenbruch Telix Pharmaceuticals Limited CEO Email: firstname.lastname@example.org Investor and Media Relations Kyahn Williamson WE Buchan Tel: +61 (3) 9866 4722 Email: email@example.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Telix Pharmaceuticals Limited via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
LM Industries Brings Manufacturing Into the Future as World's First Digital OEM20.6.2018 18:00 | Pressmeddelande
The creators of autonomous shuttle Olli form LM Industries, a company designing and building future-looking products with partners like Allianz, Airbus and the United States Marine Corps SAN FRANCISCO, June 20, 2018 (GLOBE NEWSWIRE) -- Today, the creators of the Rally Fighter and Olli announced the formation of LM Industries Group, Inc., a technology-enabled manufacturer focused on mobility products headquartered in San Francisco. LM Industries is the world's first digital OEM - which can take concepts to deployed products in under one year, all on its unique digital thread. It brings products to market in an entirely new way, designing with its global community of experts, and applying technology such as 3D printing to create and assemble products in small batches at agile microfactories. The process challenges the century-long dependency on mass manufacturing which has failed to keep up with the modern pace of technological innovation. LM Industries creates transportation, accessibil
Anglo American, Milliken & Company, MOL Group, Koch Industries, Goldcorp and AccorHotels among the Excellence Award winners at Enablon's Sustainable Performance Forum20.6.2018 17:15 | Pressmeddelande
Enablon recognizes companies for effectively leveraging technology to improve their sustainability performance CHICAGO, June 20, 2018 (GLOBE NEWSWIRE) -- Enablon, a Wolters Kluwer business and the world's leading provider of EHS, Operational Risk Management and Sustainability Software, announced today the winners of the 2018 Enablon Excellence Awards. The awards were given during a gala dinner at the Sustainable Performance Forum (SPF) in Chicago, and in Paris. The Enablon Excellence Awards recognize organizations that are leading the way within their industry and that effectively leverage technology to improve their sustainability performance to benefit their business, and also their employees, customers and the communities in which they operate. The 2018 Excellence Awards winners are: Enablon Excellence Award in EHS Performance: Koch Industries (Americas) & MOL Group (EMEA) Enablon Excellence Award in Governance, Risk & Compliance (EMEA): AccorHotels Enablon Excellence Award in Integ
Datameer Named Leader in Ovum Self-Service Data Prep Decision Matrix20.6.2018 15:40 | Pressmeddelande
Datameer ranked among top vendors for integration and exploration, data manipulation, data governance, and administration SAN FRANCISCO, June 20, 2018 (GLOBE NEWSWIRE) -- Datameer, the leader in big data management for analytics, is pleased to announce that it was named a leader in the Ovum Decision Matrix, Selecting a Self-Service Data Prep Solution, 2018-2019, ahead of Alteryx, Datawatch and Oracle. The report highlights Datameer as "a broad and complex platform [..] focused on building and managing data pipelines that enable data to be fed into any analytic tool." "In the self-service data prep market, we're increasingly seeing the trend of 'platformization' of products, whereby data prep becomes a feature rather than a stand-alone tool," said report author Paige Bartley, senior analyst at Ovum. "Datameer has taken this approach, offering a broad platform focused on data pipelines and self-service enablement. But with a broader platform and functionality comes the need for greater g
Kofax Robotic Process Automation Software Creates Smarter Robots20.6.2018 14:00 | Pressmeddelande
Kapow 10.3 Adds Artificial Intelligence, Machine Learning and Other Enhancements IRVINE, Calif., June 20, 2018 (GLOBE NEWSWIRE) -- Kofax ®, a leading supplier of software to automate and digitally transform information intensive processes, today announced the addition of artificial intelligence (AI), machine learning and other capabilities in its Kapow(TM) 10.3 Robotic Process Automation (RPA) software. Kapow, the #originalbot, automates and digitally transforms a wide range of human and information intensive processes across front and back office operations. It allows users to develop and deploy smart robots that mimic human actions while driving continuous improvement using AI and machine learning. Kapow robots interact seamlessly across desktop software, traditional enterprise and browser based systems and web sites, aggregating data, transforming it into actionable information, triggering responses, and communicating with other applications. Kapow 10.3 leverages AI and machine lear
CNP Assurances: Pre Stabilisation Notice20.6.2018 13:41 | Pressmeddelande
PARIS, June 20, 2018 (GLOBE NEWSWIRE) -- EURONEXT PARIS: CNP 20 th June 2018 CNP Assurances Stabilisation Notice HSBC (contact: 'Syndicate desk'; telephone: +44 207 992 8066) hereby gives notice, as Stabilisation Coordinator, that the Stabilisation Manager(s) named below may stabilise the offer of the following securities The securities: Issuer: CNP Assurances Guarantor (if any): Aggregate nominal amount: EUR Bmk Description: EUR Perpetual Fixed Rate Resettable Restricted Tier 1 Notes Offer price: TBC Other offer terms: Stabilisation: Stabilising Manager(s): Credit Suisse / HSBC (B&D) / Morgan Stanley / Natixis / SG CIB / Unicredit Stabilisation period expected to start on: 20th June 2018 Stabilisation period expected to end no later than: 20th July 2018 Existence, maximum size & conditions of use of over-allotment facility: 5% of the aggregate nominal amount Stabilisation Venue(s) Over the counter (OTC) In connection with the offer of the above securities, the Stabilisation Manager(s)
Delta Air Lines Becomes Launch Operator of ATMOSPHÈRE Cabin with New Order for 20 Bombardier CRJ90020.6.2018 13:00 | Pressmeddelande
MONTRÉAL, June 20, 2018 (GLOBE NEWSWIRE) -- Bombardier Commercial Aircraft announced today that Delta Air Lines, Inc. of Atlanta, Georgia (Delta Air Lines) has signed a firm purchase agreement for 20 CRJ900 aircraft - becoming the launch operator of the new ATMOSPHÈRE cabin for CRJ Series regional jets. Based on the list price for the CRJ900 aircraft, the firm order is valued at approximately US$961 million. "We are thrilled that Delta continues to select the CRJ Series as the airline looks into the future growth of its regional operations," said Fred Cromer, president, Bombardier Commercial Aircraft. "Together with Delta, we have driven the development of regional aviation in the U.S., and we are looking forward to further enhancing regional air travel with the launch of the new ATMOSPHÈRE cabin with our long-standing and esteemed customer." The new CRJ900 aircraft with ATMOSPHÈRE cabin will fly under the Delta Connection brand in a comfortable two-class regional jet configuration wit
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum